Immunogenicity of SARS-CoV-2 Vaccines in Psoriatic Patients on Ongoing Tildrakizumab Therapy: a Monocentric Observational Study

Annkathrin Schweikart; Ulf Geisen; Melike Sümbül; Bimba Hoyer; Sascha Gerdes

doi:10.5114/dr.2025.158587

Streszczenie

5/2025 vol. 112

Artykuł oryginalny

Immunogenicity of SARS-CoV-2 Vaccines in Psoriatic Patients on Ongoing Tildrakizumab Therapy: a Monocentric Observational Study

Annkathrin M. Schweikart ¹

,

Ulf M. Geisen ²

,

Melike Sümbül ¹

,

Bimba F. Hoyer ²

,

Sascha Gerdes ¹

Center for Inflammatory Skin Diseases, Department of Dermatology, Venereology and Allergology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein, Germany
Medical Department I, Department of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein, Germany

Dermatol Rev/Przegl Dermatol 2025, 112, 279–290

DOI: https://doi.org/10.5114/dr.2025.158587

Data publikacji online: 2025/12/30

Pełna treść artykułu

AMA

Schweikart AM, Geisen UM, Sümbül M, Hoyer BF, Gerdes S. Immunogenicity of SARS-CoV-2 Vaccines in Psoriatic Patients on Ongoing Tildrakizumab Therapy: a Monocentric Observational Study. Dermatology Review/Przegląd Dermatologiczny. 2025;112(5):279-290. doi:10.5114/dr.2025.158587.

APA

Schweikart, A. M., Geisen, U. M., Sümbül, M., Hoyer, B. F., & Gerdes, S. (2025). Immunogenicity of SARS-CoV-2 Vaccines in Psoriatic Patients on Ongoing Tildrakizumab Therapy: a Monocentric Observational Study. Dermatology Review/Przegląd Dermatologiczny, 112(5), 279-290. https://doi.org/10.5114/dr.2025.158587

Chicago

Schweikart, Annkathrin M, Ulf M Geisen, Melike Sümbül, Bimba F Hoyer, and Sascha Gerdes. 2025. "Immunogenicity of SARS-CoV-2 Vaccines in Psoriatic Patients on Ongoing Tildrakizumab Therapy: a Monocentric Observational Study". Dermatology Review/Przegląd Dermatologiczny 112 (5): 279-290. doi:10.5114/dr.2025.158587.

Harvard

Schweikart, A., Geisen, U., Sümbül, M., Hoyer, B., and Gerdes, S. (2025). Immunogenicity of SARS-CoV-2 Vaccines in Psoriatic Patients on Ongoing Tildrakizumab Therapy: a Monocentric Observational Study. Dermatology Review/Przegląd Dermatologiczny, 112(5), pp.279-290. https://doi.org/10.5114/dr.2025.158587

MLA

Schweikart, Annkathrin et al. "Immunogenicity of SARS-CoV-2 Vaccines in Psoriatic Patients on Ongoing Tildrakizumab Therapy: a Monocentric Observational Study." Dermatology Review/Przegląd Dermatologiczny, vol. 112, no. 5, 2025, pp. 279-290. doi:10.5114/dr.2025.158587.

Vancouver

Schweikart A, Geisen U, Sümbül M, Hoyer B, Gerdes S. Immunogenicity of SARS-CoV-2 Vaccines in Psoriatic Patients on Ongoing Tildrakizumab Therapy: a Monocentric Observational Study. Dermatology Review/Przegląd Dermatologiczny. 2025;112(5):279-290. doi:10.5114/dr.2025.158587.

Streszczenie

Immunogenicity of SARS-CoV-2 Vaccines in Psoriatic Patients on Ongoing Tildrakizumab Therapy: a Monocentric Observational Study

Udostępnij

Dostępne w

Zintergrowane z

Zasady redakcyjne